Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43313 | 0.87 | MAPK1 (0.46) | ALDH1A1MAPTMAPK1RAB9ANPC1 | |
| SCHEMBL18824888 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTMAPK1RAB9ANPC1 | |
| SCHEMBL4188808 | 0.79 | KIF11 (0.41) | ALDH1A1MAPK1KIF11ALOX15 | |
| SCHEMBL18253223 | 0.79 | TSHR (0.50) | ALDH1A1MAPTMAPK1RAB9ANPC1 | |
| SCHEMBL1172625 | 0.78 | ALDH1A1 (0.48) | ALDH1A1MAPTMAPK1RAB9ANPC1 | |
| SCHEMBL28329682 | 0.78 | ALDH1A1 (0.60) | ALDH1A1MAPTMAPK1RAB9ANPC1 | |
| SCHEMBL10447173 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MAPTMAPK1RAB9ANPC1 | |
| SCHEMBL9508337 | 0.77 | TSHR (0.55) | ALDH1A1MAPTMAPK1RAB9ANPC1 | |
| SCHEMBL17306153 | 0.76 | CYP2D6 (0.44) | ALDH1A1MAPK1RAB9ANPC1HPGD | |
| SCHEMBL23113609 | 0.75 | HSD17B10 (0.41) | ALDH1A1MAPTMAPK1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697993-B | Pyrimidine compounds as AXL inhibitors | 南京正大天晴制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| EP-3628044-B1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| EP-4163278-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2023-04-12 | — | — | EP | disclosed |
| CN-115697993-A | Pyrimidines as AXL inhibitors | 南京正大天晴制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021239133-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | 南京正大天晴制药有限公司 | 2021-12-02 | — | — | WO | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20080108623-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108623-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108623-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | US | disclosed |
| US-7300935-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-11-27 | — | — | US | disclosed |
| US-7300935-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-11-27 | — | — | US | disclosed |
| US-7300935-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20060160829-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1591446-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-20050222174-A1 | Thienopyrimidines, process for preparing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1479684-A1 | THIENOPYRIMIDINES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160829-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | GNRHR, KISS1R, FSHR | ALDH1A1 2600/4885MAPT 4837/4885MAPK1 907/4885 |
| US-20050222174-A1 | Thienopyrimidines, process for preparing the same and use thereof | GNRHR, CRH, CYP19A1 | ALDH1A1 2092/4885MAPT 4799/4885MAPK1 1471/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ALDH1A1 4333/4885MAPT 470/4885MAPK1 309/4885 |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | ALDH1A1 2696/4885MAPT 2663/4885MAPK1 293/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | ALDH1A1 4184/4885MAPT 438/4885MAPK1 280/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | ALDH1A1 4184/4885MAPT 438/4885MAPK1 280/4885 |
| US-20080108623-A1 | N-(4-(1-(2,6-difluorobenzyl)-5(((2-methoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea; gonadotropin releasing hormone (GnRH) antagonist; sex hormone dependent disease, antitumor agent | GNRHR, KISS1R, FSHR | ALDH1A1 2600/4885MAPT 4837/4885MAPK1 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.